A Phase 4 interventional study of Donepezil HCL in Alzheimer's Disease, sponsored by Eisai Korea Inc.. Completed at 13 sites in Korea, Republic of. Open to participants aged 45 Years to 90 Years. Per ClinicalTrials.gov, last updated 2016-06-27.
Sponsored by Eisai Korea Inc. (part of Eisai Co., Ltd.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.
Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 18th largest by enrollment of the 58 interventional ones that give a count, is one of 6 that started in 2014, is one of 20 in phase 4, and was the 42nd registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 50+
Eisai Inc.
Ages 50–85
By country, each count listing its studies:
Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 45 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 6 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 171 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 79 across the 58 interventional studies. Of the 56 that completed or were terminated, 21 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Korea Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Korea Inc. is the lead sponsor of 31 studies on the registry; 2 are open to participants now.
46 studies in Alzheimer Disease by Eisai Co., Ltd.: 7 open now, 12 under way, 2 of them phase 3. Of 33 finished, 11 (33%) have results posted.
Among the 46 studies in Alzheimer Disease by Eisai Co., Ltd., this one is the 12th largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2014, is one of 9 in phase 4, and was the 25th registered.
Eisai Co., Ltd.’s Alzheimer Disease studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 60 studies testing donepezil in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eisai Co., Ltd.’s 46 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, open-label, single-arm, prospective, phase IV trial, evaluating safety and efficacy of donepezil hydrochloride in patients with moderate to severe Alzheimer's disease.
This study consisted of pre-treatment and treatment phase. Pre-treatment phase was approximately 4 weeks including the screening and baseline process. In treatment phase, about 190 subjects received Donepezil HCl 23 mg once daily for 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
Drug: Donepezil HCL
Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
Overall Summary of Adverse Events (AEs)
Safety of study drug was assessed by clinical laboratory assessments, vital signs, weight, 12-lead electrocardiogram (ECG), physical and neurological examination. Treatment-Emergent Adverse Events (TEAEs) were defined as any event not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. Serious adverse events were defined as AEs that led to or were life-threatening, resulted in or prolonged hospitalization, caused important or long-lasting disability, caused congenital abnormality or malformation, or resulted in death. Adverse drug reactions were defined as any harmful or unintended reaction to study treatment and were considered possibly related or probably related to study drug. Specific AEs and SAEs due to changes in clinical laboratory assessments, vital signs, weight, ECG, and physical and neurological exam are listed in the safety section.
Time frame: Baseline (Day 1) up to Week 24
Change From Baseline in the Mini-Mental State Examination (MMSE) Score
The MMSE was used to measure cognitive impairment. The MMSE can evaluate overall cognitive function, and is widely used for the assessment of cognitive impairment in dementia patients. The questionnaire consists of 11 items, and each item aims to evaluate different cognitive domains such as orientation, memory, attention, and construction. The score ranged from 0 to 30, with a higher score indicating better function. A positive change score indicated improvement from baseline. The mean change was analyzed by Wilcoxon's signed rank test.
Time frame: Baseline, Week 12, and Week 24 (Final visit)
Change From Baseline in the Neuropsychiatric Inventory Questionnaire (NPI-Q) Severity and Distress Total Scores
The NPI-Q assessed twelve behavioral domains common in dementia including; hallucinations, delusions, agitation/aggression, dysphoria/depression, anxiety, irritability, disinhibition, euphoria, apathy, aberrant motor behavior, sleep/night-time behavior change, and appetite/eating change. The questionnaire is given by the clinician to the patient's caregiver who was asked if the behavior described is present in the patient. If "Yes", the informant then rates both the Severity of the symptoms present within the last month on a 3-point scale (1 = mild, 2= moderate, and 3= severe) and the associated impact of the symptom manifestations on them (i.e. Caregiver Distress) using a 5-point scale (0 = not distressing at all, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = extreme or very severe). The total severity score represents the sum of individual scores and ranges from 0 to 36. The total distress score represents the sum of individual symptom scores and ranges from 0 to 60.
Time frame: Baseline, Week 12, and Week 24 (Follow up visit)
| Milestone | Donepezil Hydrochloride |
|---|---|
| Started | 171 |
| Participantstreated | 170 |
| Completed | 113 |
| Not completed | 58 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Withdrawal by subject | 15 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Adverse event | 37 |
| Withdrew: Other | 2 |
Safety of study drug was assessed by clinical laboratory assessments, vital signs, weight, 12-lead electrocardiogram (ECG), physical and neurological examination. Treatment-Emergent Adverse Events (TEAEs) were defined as any event not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. Serious adverse events were defined as AEs that led to or were life-threatening, resulted in or prolonged hospitalization, caused important or long-lasting disability, caused congenital abnormality or malformation, or resulted in death. Adverse drug reactions were defined as any harmful or unintended reaction to study treatment and were considered possibly related or probably related to study drug. Specific AEs and SAEs due to changes in clinical laboratory assessments, vital signs, weight, ECG, and physical and neurological exam are listed in the safety section.
| Percentage of participants | Donepezil Hydrochloride |
|---|---|
| AEs | 67.65 |
| ADRs | 47.06 |
| SAEs | 7.06 |
| Serious ADRs | 0.59 |
The MMSE was used to measure cognitive impairment. The MMSE can evaluate overall cognitive function, and is widely used for the assessment of cognitive impairment in dementia patients. The questionnaire consists of 11 items, and each item aims to evaluate different cognitive domains such as orientation, memory, attention, and construction. The score ranged from 0 to 30, with a higher score indicating better function. A positive change score indicated improvement from baseline. The mean change was analyzed by Wilcoxon's signed rank test.
| Scores on a scale | Donepezil Hydrochloride |
|---|---|
| Change W12 | -0.31 ± 2.76 |
| Change W24 | -0.40 ± 2.75 |
The NPI-Q assessed twelve behavioral domains common in dementia including; hallucinations, delusions, agitation/aggression, dysphoria/depression, anxiety, irritability, disinhibition, euphoria, apathy, aberrant motor behavior, sleep/night-time behavior change, and appetite/eating change. The questionnaire is given by the clinician to the patient's caregiver who was asked if the behavior described is present in the patient. If "Yes", the informant then rates both the Severity of the symptoms present within the last month on a 3-point scale (1 = mild, 2= moderate, and 3= severe) and the associated impact of the symptom manifestations on them (i.e. Caregiver Distress) using a 5-point scale (0 = not distressing at all, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = extreme or very severe). The total severity score represents the sum of individual scores and ranges from 0 to 36. The total distress score represents the sum of individual symptom scores and ranges from 0 to 60.
| Scores on a scale | Donepezil Hydrochloride |
|---|---|
| Change Week 12 (Severity) | 0.33 ± 4.74 |
| Change Week 24 (Severity) | 0.09 ± 5.67 |
| Change Week 12 (Distress) | 0.19 ± 6.83 |
| Change Week 24 (Distress) | 0.29 ± 7.60 |
Collected over AEs were collected from Day 1 through Week 24 of study.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Donepezil Hydrochloride | — | 12/170 (7.1%) | 109/170 (64.1%) |
| Event | Donepezil Hydrochloride |
|---|---|
| Femur fractureInjury, poisoning and procedural complications | 2/170 |
| Rib fractureInjury, poisoning and procedural complications | 2/170 |
| Ankle fractureInjury, poisoning and procedural complications | 1/170 |
| Cervical vertebral fractureInjury, poisoning and procedural complications | 1/170 |
| Ligament injuryInjury, poisoning and procedural complications | 1/170 |
| Lumbar vertebral fractureInjury, poisoning and procedural complications | 1/170 |
| DiarrhoeaGastrointestinal disorders | 1/170 |
| Gait disturbanceGeneral disorders | 1/170 |
| PneumoniaInfections and infestations | 1/170 |
| Decreased appetiteMetabolism and nutrition disorders | 1/170 |
| Event | Donepezil Hydrochloride |
|---|---|
| NauseaGastrointestinal disorders | 21/170 |
| VomitingGastrointestinal disorders | 19/170 |
| Decreased appetiteMetabolism and nutrition disorders | 16/170 |
| DizzinessNervous system disorders | 13/170 |
| DiarrhoeaGastrointestinal disorders | 11/170 |
| LethargyNervous system disorders | 8/170 |
| HeadacheNervous system disorders | 6/170 |
| SomnolenceNervous system disorders | 6/170 |
| AnxietyPsychiatric disorders | 6/170 |
| Urinary incontinenceRenal and urinary disorders | 6/170 |
Safety population included all participants who received at least one dose of study treatment and had at least one postbaseline safety assessment.
| Age, Continuous(Years) | Donepezil Hydrochloride |
|---|---|
| Mean | 74.82 ± 7.18 |
| Sex: Female, Male(Participants) | Donepezil Hydrochloride |
|---|---|
| Female | 123 |
| Male | 47 |
The record gives a start of Feb 2014, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donepezil